

Express Mail Label No. L862265702US  
Date of Deposit: October 16, 2001

cket No.: 24065-004CON

**APPLICATION  
FOR  
UNITED STATES LETTERS PATENT**

**TITLE: MUTATIONS ASSOCIATED WITH IRON DISORDERS**

**APPLICANTS: BARRY E. ROTENBERG, RITSUKO SAWADA-HIRAI AND  
JAMES C. BARTON**

RECEIVED - 10/16/2001

MUTATIONS ASSOCIATED WITH IRON DISORDERS

Background of the Invention

5       Hemochromatosis is the most common progressive (and sometimes fatal) genetic disease in people of European descent. Hemochromatosis is a disease state characterized by an inappropriate increase in intestinal iron absorption. The increase can result in deposition of iron in organs such 10      as the liver, pancreas, heart, and pituitary. Such iron deposition can lead to tissue damage and functional impairment of the organs.

In some populations, 60-100% of cases are attributable to homozygosity for a missense mutation at 15      C282Y in the Histocompatibility iron (Fe) loading (HFE) gene, a major histocompatibility (MHC) non-classical class I gene located on chromosome 6p. Some patients are compound heterozygotes for C282Y and another mutation at H63D.

Summary of the Invention

The invention is based on the discovery of novel mutations which are associated with aberrant iron metabolism, absorption, or storage, or in advanced cases, clinical hemochromatosis. Accordingly, the invention features a method of diagnosing an iron disorder, e.g., hemochromatosis or a genetic susceptibility to developing such a disorder, in a mammal by determining the presence of a mutation in exon 2 of an HFE nucleic acid. The mutation is not a C->G missense mutation at position 187 of SEQ ID NO:1 which leads to a H63D substitution. The nucleic acid 20      is an RNA or DNA molecule in a biological sample taken from the mammal, e.g. a human patient, to be tested. The presence of the mutation is indicative of the disorder or a genetic susceptibility to developing it. An iron disorder 25      is characterized by an aberrant serum iron level, ferritin 30      level, or percent saturation of transferrin compared to the 35

level associated with a normal control individual. An iron overload disorder is characterized by abnormally high iron absorption compared to a normal control individual.

Clinical hemochromatosis is defined by an elevated fasting 5 transferrin saturation level of greater than 45% saturation.

For example, the mutation is a missense mutation at nucleotide 314 of SEQ ID NO:1 such as 314C which leads to the expression of mutant HFE gene product with amino acid substitution I105T. The I105T mutation is located in the 10  $\alpha$ 1 helix of the HFE protein and participates in a hydrophobic pocket (the "F" pocket). The alpha helix structure of the  $\alpha$ 1 domain spans residues S80 to N108, inclusive. The I105T mutation is associated with an iron overload disorder.

Table 1: Human HFE cDNA sequence

15	atggggcccg cgagccaggc
20	cggcgcttct cctccgtatg cttttcaga ccgcggtcct gcaggggcgc ttgctgcgtt cacactctct gcaactacctc ttcatgggtg cctcagagca ggaccttggt ctttccctgt ttgaagcttt gggctacgtg gatgaccaggc tggctgtgtt ctatgatcat <u>gagaqtcgcc</u> <u>H63D</u> <u>S65C</u>
25	gtgtggagcc ccgaactcca tgggtttcca gtagaatttc aagccagatg tggctgcagc tgagttagag tctgaaaggq tgggatcaca tgttcaactgt tgacttctgg actattatgg <u>G93R</u>
30	aaaatcacaa ccacagcaag gagtcccaca ccctgcaggc catcctggc tgtgaardgc aagaagacaa cagtaccgag ggctactgga agtacgggt tgatggcag gaccacctg aattctgccc tgacacactg gattggagag cagcagaacc cagggcctgg cccaccaagc tggagtggga aaggcacaag attcggccca ggcagaaacag ggcctacctg gagaggact gccctgcaca gctgcagc ttgctggagc tggggagagg tggggatggc caacaagtgc ctcccttgggt gaagggtaca catcatgtg catcatgtg ccttcttgc gaccactcta cggtgtcggg ccttgaacta ctacccccag aacatcacca tgaagtggct gaaggataag cagccaatgg atgccaagga gttcaaccc aaagacgtat tgcccaatgg ggtatgggacc taccaggc ggataaccc ggctgtaccc cctggggaaag agcagagata tacgtgccag gtggagcacc caggcctgga tcagccctc attgtgatct gggagccctc accgtctggc accctagtca ttggagtcatt cagtggaaatt gctgttttg tcgtcatctt gtcattggaa attttttca 35 taatattaag gaagaggcag ggttcaagag gagccatggg gcaactacgta ttagctgaac gtgagtgaca cgcagccgc agactcaactg tgggaaggag acaaaactag agactcaaag agggagtgca tttatgatgt cttcatgtttt caggagagat ttgaacctaa acatagaat tgccctgacga actccctgtat tttagccctt tctgttatt tcctcaaaaa gatcccca 40 ttaggtttc tgatgttgc catgccgggt atcccttagct gtgacccctc ccctggaaact gtctctcatg aaccccaagg tgcatttgc ggtttccctc atttcctccg tcacccatc gacatacacc tatgtcattt catttcattt ttttggaaaga ggactcccttta aatttgggg acttacatga ttcatatggaa catctggaa aagcttggaa ccctgggacg tggcttagtca taacccatcc agattttac acatgttatct atgcattttc tggaccctt caactttcc 45 tttgaatcc ctctctgtt taccctgtt ctcattgttcc accaaggcctt ggggattctt ccatctgtt gttatgttgc ttgcacagct atgaaggctg tgcactgcac gaatggaaaga ggcacctgtc ccagaaaaag catcatggct atctgtgggt agatgtatgg gtgttttag caggttaggag gcaaatatct taaaagggggt tggtaagagg tggggatgtt aattggcatg aagggtgtcat acagatttgc aaagtttaat ggtgccttca tttggatgc tactctagta

ttccagacat gaagaatcac aataatttc tacctggctc ctccctgttc tgataatgaa  
aattatgata agatgataa aagcaattac ttcgtgtcc actcttctga gcacctactt  
5 acatgcatta ctgcattcac ttcttacaat aattctatga gataggact attatccccca  
tttctttttt aaatgaagaa agtgaagtag gccgggcacg gtggctcg cctgtggtcc  
cagggtgctg agattgcagg tgtgagccac cctgcccacg cgtaaaaaga gtcttaatat  
atatatccag atggcatgtg tttactttat gttactacat gcacttggct gcataaaatgt  
gttacaacca ttctgtcttg aagggcaggt gttcaggat accatataca gtcagaagt  
10 ttcttcttta ggcattaaat tttagcaaag atatctcattc tcttcttta aaccatttc  
ttttttgtg gttagaaaag ttatgtagaa aaaagtaaat gtgatttacg ctcattgttag  
aaaagctata aaatgaatac aattaaagct gttatttaat tagccagtga aaaactattaa  
acaacttgc tattacctgt tagtattttt gttgcattaa aaatgcatac actttaataa  
atgtacattg tattgtaaaa aaaaaaaaa

(SEQ ID NO:1; GENBANK® Accession No. U60319)

Table 2: Human HFE gene product

15 MGPRARPALLLMLLQTAVLQG  
RLLRSHSLHYLFMGASEQDLGLSLFEALGYVDDQLFVFYDHESRRVEPRTPWSSRISSQ  
MWLOLSOSLKGWDHMFTVDFWTIMENHNHSKESHTLQVILGCEMQEDNSTEGYWKYGYDG  
QDHLEFCPDTLDWRAAEPRRAWPTKLEWERHKIRARQNRAYLERDCPAQLQQLLGRGVLI  
DQQVPPPLVKVTTHVTSSVTTLRCRALNYYQPQNITMKWLKDQPMDAKEFEPKDVLPGNDG  
20 TYQGWITLAVPPGEEQRYTCQVEHPGLDQPLIVIWEPSGTLVIGVISGIAVFVVLIFI  
GILFIIILRKRQGSRGAMGHYVLAERE (SEQ ID NO: 2; GENBANK® Accession  
No. U60319)

Residues 1-22 = leader sequence; α1 domain underlined;  
residues 63, 65, 93, and 105 indicated in bold type)

25 Other mutations include nucleotide 277 of SEQ ID NO: 1,  
e.g., 277C which leads to expression of mutant HFE gene  
product G93R and one at nucleotide 193 of SEQ ID NO: 1,  
e.g., 193T, which leads to expression of mutant HFE gene  
product S65C.

30 Any biological sample containing an HFE nucleic acid  
or gene product is suitable for the diagnostic methods  
described herein. For example, the biological sample to be  
analyzed is whole blood, cord blood, serum, saliva, buccal  
tissue, plasma, effusions, ascites, urine, stool, semen,  
35 liver tissue, kidney tissue, cervical tissue, cells in  
amniotic fluid, cerebrospinal fluid, hair or tears.  
Prenatal testing can be done using methods used in the art,  
e.g., amniocentesis or chorionic villa sampling.  
Preferably, the biological sample is one that can be non-

invasively obtained, e.g., cells in saliva or from hair follicles.

The assay is also used to screen individuals prior to donating blood to blood banks and to test organ tissue,  
5 e.g., a donor liver, prior to transplantation into a recipient patient. Both donors and recipients are screened.

In some cases, a nucleic acid is amplified prior to detecting a mutation. The nucleic acid is amplified using a first oligonucleotide primer which is 5' to exon 2 and a second oligonucleotide primer is 3' to exon 2. To detect mutation at nucleotide 314 of SEQ ID NO: 1, a first oligonucleotide primer which is 5' to nucleotide 314 and a second oligonucleotide primer which is 3' to nucleotide 314 is used in a standard amplification procedure such as  
10 polymerase chain reaction (PCR). To amplify a nucleic acid containing nucleotide 277 of SEQ ID NO: 1, a first oligonucleotide primer which is 5' to nucleotide 277 and a second oligonucleotide primer which is 3' to nucleotide 277 is used. Similarly, a nucleic acid containing nucleotide  
15 193 of SEQ ID NO:1 is amplified using primers which flank that nucleotide. For example, for nucleotide 277, the first primer has a nucleotide sequence of SEQ ID NO: 3 and said second oligonucleotide primer has a nucleotide sequence of SEQ ID NO: 4, or the first primer has a nucleotide sequence  
20 of SEQ ID NO: 15 and said second oligonucleotide primer has a nucleotide sequence of SEQ ID NO: 16. Table 3, below, shows examples of primer pairs for amplification of nucleic acids in exons and introns of the HFE gene.  
25

Table 3

I. PRIMERS USED FOR AMPLIFICATION		
Target DNA	Forward Primer	Reverse Primer
Exon 2	CCTCCTACTACACATGGTTAAGG (SEQ ID NO: 3)	GCTCTGACAACCTCAGGAAGG (SEQ ID NO: 4)
Exon 3	GGTGGAAATAGGGACCTATTCC (SEQ ID NO: 5)	CACTCTGCCACTAGACTATAGG (SEQ ID NO: 6)
Exon 4	GTTCCAGTCTTCCTGGCAAGG (SEQ ID NO: 7)	AAATGCTTCCCATTGGATGCCAG (SEQ ID NO: 8)
RT-PCR	AAAGGATCCACCATGGGCCCGCAGCCAGG (SEQ ID NO: 9)	GTGAGTCTGCAGGCTGCGTG (SEQ ID NO: 10)
Intron 4	GTTCCAGTCTTCCTGGCAAGG (SEQ ID NO: 11)	AAATGCTTCCCATTGGATGCCAG (SEQ ID NO: 12)
Intron 5	GTTCCAGTCTTCCTGGCAAGG (SEQ ID NO: 13)	AAATGCTTCCCATTGGATGCCAG (SEQ ID NO: 14)
II. PRIMERS USED FOR AMPLIFICATION		
Target DNA	Forward Primer	Reverse Primer
Exon 2	GTTGGAGCCTAACATCCTG (SEQ ID NO: 15)	ACAAGACCTCAGACTTCCAGC (SEQ ID NO: 16)
Exon 3	GGTGGAAATAGGGACCTATTCC (SEQ ID NO: 17)	CACTCTGCCACTAGAGTATAGG (SEQ ID NO: 18)
Exon 4	GTTCCAGTCTTCCTGGCAAGG (SEQ ID NO: 19)	TTACCTCCTCAGGCACTCCTC (SEQ ID NO: 20)
RT-PCR	AAAGGATCCACCATGGGCCCGCAGCCAGG (SEQ ID NO: 21)	GTGAGTCTGCAGGCTGCGTG (SEQ ID NO: 22)
Intron 4	TGCCTGAGGAGGTAAATTATGG (SEQ ID NO: 23)	AAATGCTTCCCATTGGATGCCAG (SEQ ID NO: 24)
Intron 5	TGCCTGAGGAGGTAAATTATGG (SEQ ID NO: 25)	AAATGCTTCCCATTGGATGCCAG (SEQ ID NO: 26)

Mutations in introns of the HFE gene have now been associated with iron disorders and/or hemochromatosis. By "exon" is meant a segment of a gene the sequence of which is represented in a mature RNA product, and by "intron" is meant a segment of a gene the sequence of which is not represented in a mature RNA product. An intron is a part of a primary nuclear transcript which is subsequently spliced out to produce a mature RNA product, i.e., a mRNA, which is then transported to the cytoplasm. A method of diagnosing an iron disorder or a genetic susceptibility to developing the disorder is carried out by determining the presence or absence of a mutation in an intron of HFE genomic DNA in a biological sample. The presence of the mutation is indicative of the disorder or a genetic susceptibility to developing the disorder. The presence of a mutation in an intron is a marker for an exon mutation, e.g., a mutation in intron 4, e.g., at nucleotide 6884 of SEQ ID NO:27 is associated with the S65C mutation in exon 2. A mutation in intron 5, e.g., at nucleotide 7055 of SEQ ID NO:27 is associated with hemochromatosis. In some cases, intron mutations may adversely affect proper splicing of exons or may alter regulatory signals. Preferably, the intron 4 mutation is 6884C and the intron 5 mutation is 7055G. To amplify nucleic acid molecule containing nucleotide 6884 or 7055, primers which flank that nucleotide, e.g., those described in Table 3, are used according to standard methods. Nucleic acid-based diagnostic methods may or may not include a step of amplification to increase the number of copies of the nucleic acid to be analyzed. To detect a mutation in intron 4, a patient-derived nucleic acid may be amplified using a first oligonucleotide primer which is 5' to intron 4 and a second oligonucleotide primer which is 3'

to intron 4, and to detect a mutation in intron 5, the nucleic acid may be amplified using a first oligonucleotide primer which is 5' to intron 5 and a second oligonucleotide primer which is 3' to intron 5 (see, e.g., Table 3).

5 In addition to nucleic acid-based diagnostic methods, the invention includes a method of diagnosing an iron overload disorder or a genetic susceptibility thereto by determining the presence of a mutation in a HFE gene product in a biological sample. For example, the mutation 10 results in a decrease in intramolecular salt bridge formation in the mutant HFE gene product compared to salt bridge formation in a wild type HFE gene product. The mutation which affects salt bridge formation is at or proximal to residue 63 of SEQ ID NO:2, but is not amino acid 15 substitution H63D. Preferably, the mutation is between residues 23-113, inclusive of SEQ ID NO:2 (Table 2), more preferably, it is between residues 90-100, inclusive, of SEQ ID NO:2, more preferably, it is between residues 58-68, inclusive, of SEQ ID NO:2, and most preferably, the mutation 20 is amino acid substitution S65C. Alternatively, the mutation which affects salt bridge formation is a mutation, e.g., an amino acid substitution at residue 95 or proximal to residue 95 of SEQ ID NO:2. Preferably, the mutation is G93R. Such an HFE mutation is detected by immunoassay or 25 any other ligand binding assay such as binding of the HFE gene product to a transferrin receptor. Mutations are also detected by amino acid sequencing, analysis of the structural conformation of the protein, or by altered binding to a carbohydrate or peptide mimotope.

30 A mutation indicative of an iron disorder or a genetic susceptibility to developing such a disorder is located in the  $\alpha 1$  helix (e.g., which spans residues 80-108, inclusive, of SEQ ID NO:2) of an HFE gene product. The

mutation may be an addition, deletion, or substitution of an amino acid in the wild type sequence. For example, the mutant HFE gene product contains the amino acid substitution I105T or G93R or in the loop of the  $\beta$  sheet of the HFE molecule, e.g., mutation S65C

Isolated nucleic acids encoding a mutated HFE gene products (and nucleic acids with nucleotide sequences complementary to such coding sequences) are also within the invention. Also included are nucleic acids which are at least 12 but less than 100 nucleotides in length. An isolated nucleic acid molecule is a nucleic acid molecule that is separated from the 5' and 3' sequences with which it is immediately contiguous in the naturally occurring genome of an organism. "Isolated" nucleic acid molecules include nucleic acid molecules which are not naturally occurring. For example, an isolated nucleic acid is one that has been amplified *in vitro*, e.g., by PCR; recombinantly produced; purified, e.g., by enzyme cleavage and gel separation; or chemically synthesized. For example, the restriction enzyme, Bst4C I (Sib Enzyme Limited, Novosibirsk, Russia), can be used to detect the G93R mutation (point mutation 277C); this enzyme cuts the mutated HFE nucleic acid but not the wild type HFE nucleic acid. Such nucleic acids are used as markers or probes for disease states. For example, a marker is a nucleic acid molecule containing a nucleotide polymorphism, e.g., a point mutation, associated with an iron disorder disease state flanked by wild type HFE sequences. The invention also encompasses nucleic acid molecules that hybridize, preferably under stringent conditions, to a nucleic acid molecule encoding a mutated HFE gene product (or a complementary strand of such a molecule). Preferably the hybridizing nucleic acid molecule is 400 nucleotides, more preferably 200 nucleotides, more

preferably 100, more preferably 50, more preferably  
25 nucleotides, more preferably 20 nucleotides, and most  
preferably 10-15 nucleotides, in length. For example, the  
nucleotide probe to detect a mutation is 13-15 nucleotides  
5 long. The nucleic acids are also used to produce  
recombinant peptides for generating antibodies specific for  
mutated HFE gene products. In preferred embodiments, an  
isolated nucleic acid molecule encodes an HFE polypeptide  
containing amino acid substitution I105T, G93R, or S65C, as  
10 well as nucleic acids the sequence of which are  
complementary to such nucleic acid which encode a mutant or  
wild type HFE gene product.

Also within the invention are substantially pure  
15 mutant HFE gene products, e.g., an HFE polypeptide  
containing amino acid substitution I105T, G93R, or S65C.  
Substantially pure or isolated HFE polypeptides include  
those that correspond to various functional domains of HFE  
or fragments thereof, e.g., a fragment of HFE that contains  
the  $\alpha$ 1 domain.

20 Wild type HFE binds to the transferrin receptor and  
regulates the affinity of transferrin receptor binding to  
transferrin. For example, a C282Y mutation in the HFE gene  
product reduces binding to the transferrin receptor, thus  
allowing the transferrin receptor to bind to transferrin  
25 (which leads to increased iron absorption).

The polypeptides of the invention encompass amino  
acid sequences that are substantially identical to the amino  
acid sequence shown in Table 2 (SEQ ID NO:2). Polypeptides  
of the invention are recombinantly produced, chemically  
30 synthesized, or purified from tissues in which they are  
naturally expressed according to standard biochemical  
methods of purification. Biologically active or functional  
polypeptides are those which possess one or more of the

biological functions or activities of wild type HFE, e.g.,  
binding to the transferrin receptor or regulation of binding  
of transferrin to the transferrin receptor. A functional  
polypeptide is also considered within the scope of the  
invention if it serves as an antigen for production of  
antibodies that specifically bind to an HFE epitope. In  
many cases, functional polypeptides retain one or more  
domains present in the naturally-occurring form of HFE.

The functional polypeptides may contain a primary  
amino acid sequence that has been altered from those  
disclosed herein. Preferably, the cysteine residues in  
exons 3 and 4 remain unchanged. Preferably the  
modifications consist of conservative amino acid  
substitutions. The terms "gene product", "protein", and  
"polypeptide" are used herein to describe any chain of amino  
acids, regardless of length or post-translational  
modification (for example, glycosylation or  
phosphorylation). Thus, the term "HFE polypeptide or gene  
product" includes full-length, naturally occurring HFE  
protein, as well a recombinantly or synthetically produced  
polypeptide that correspond to a full-length naturally  
occurring HFE or to a particular domain or portion of it.

The term "purified" as used herein refers to a  
nucleic acid or peptide that is substantially free of  
cellular material, viral material, or culture medium when  
produced by recombinant DNA techniques, or chemical  
precursors or other chemicals when chemically synthesized.  
Polypeptides are said to be "substantially pure" when they  
are within preparations that are at least 60% by weight (dry  
weight) the compound of interest. Preferably, the  
preparation is at least 75%, more preferably at least 90%,  
and most preferably at least 99%, by weight the compound of  
interest. Purity can be measured by any appropriate

DEPARTMENT OF  
THE PATENT AND TRADEMARK OFFICE

standard method, for example, by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

Diagnostic kits for identifying individuals suffering from or at risk of developing an iron disorder are also within the invention. A kit for detecting a nucleotide polymorphism associated with an iron disorder or a genetic susceptibility thereto contains an isolated nucleic acid which encodes at least a portion of the wild type or mutated HFE gene product, e.g., a portion which spans a mutation diagnostic for an iron disorder or hemochromatosis (or a nucleic acid the sequence of which is complementary to such a coding sequence). A kit for the detection of the presence of a mutation in exon 2 of an HFE nucleic acid contains a first oligonucleotide primer which is 5' to exon 2 and a second oligonucleotide primer is 3' to exon 2, and a kit for an antibody-based diagnostic assay includes an antibody which preferentially binds to an epitope of a mutant HFE gene product, e.g., an HFE polypeptide containing amino acid substitution I105T, G93R, or S65C, compared to its binding to the wild type HFE polypeptide. An increase in binding of the mutant HFE-specific antibody to a patient-derived sample (compared to the level of binding detected in a wild type sample or sample derived from a known normal control individual) indicates the presence of a mutation which is diagnostic of an iron disorder, i.e., that the patient from which the sample was taken has an iron disorder or is at risk of developing one. The kit may also contain an antibody which binds to an epitope of wild type HFE which contains residue 105, 93, or 65. In the latter case, reduced binding of the antibody to a patient-derived HFE gene product (compared to the binding to a wild type HFE gene product or a gene product derived from a normal control individual) indicates the presence of a mutation which is

DRAFT  
1.0  
10/16/2014

diagnostic of an iron disorder, i.e., that the patient from which the sample was taken has an iron disorder or is at risk of developing one.

Individual mutations and combinations of mutations in the HFE gene are associated with varying severity of iron disorders. For example, the C282Y mutation in exon 4 is typically associated with clinical hemochromatosis, whereas other HFE mutations or combinations of mutations in HFE nucleic acids are associated with disorders of varying prognosis. In some cases, hemochromatosis patients have been identified which do not have a C282Y mutation. The I105T and G93R mutations are each alone associated with an increased risk of iron overload (compared to, e.g., the H63D mutation alone), and the presence of both the I105T and H63D mutation is associated with hemochromatosis. Accordingly, the invention includes a method of determining the prognosis for hemochromatosis in a mammal suffering from or at risk of developing said hemochromatosis by (a) detecting the presence or absence of a first mutation in exon 4 in each allele of an HFE nucleic acid, e.g., patient-derived chromosomal DNA, and (b) detecting the presence of a second mutation in exon 2 in each allele of the nucleic acid. The presence of the first mutation in both chromosomes, i.e. an exon 4 homozygote such as a C282Y homozygote, indicates a more negative prognosis compared to the presence of the second mutation in one or both chromosomes, i.e., an exon 2 heterozygote or homozygote. An exon 4 mutation homozygote is also associated with a more negative prognosis compared to the presence of a first mutation (exon 4) in one allele and the presence of the second mutation (exon 2) in one allele, i.e., a compound heterozygote.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

Brief Description of the Drawings

Fig. 1 is a diagram of the family of proband 1 (HFE genotype H63D/I105T). □ = male, ● = female, Ø = deceased, ■ = hemochromatosis phenotype. Proband 1 is indicated by an arrow. Phenotype and genotype data: age in year saturation; % Ftn = serum ferritin concentration. I105 separate chromosomes. The sister of the proband (II, 203) has hyperferritinemia.

Fig. 2 is a diagram of the family of proband 2 (HFE genotype C282Y/G93R). Symbols and abbreviations are the same as those described for Fig. 1. Proband 2 is indicated with an arrow. G93R, C282Y, and wt alleles are known to exist only on separate chromosomes. The father and sister of the proband are being treated for hemochromatosis.

Fig. 3 is a diagram of the family of proband 3 (HFE genotype C282Y/S65C). Symbols and abbreviations are the same as those described for Fig. 1. Proband 3 is indicated with an arrow. S65C, C282Y, and wt alleles are known to exist only on separate chromosomes. Proband 3 also has porphyria cutanea tarda, and her brother (II, 203) has ankylosing spondylitis.

Detailed Description

A proband is the first individual in a family identified to be affected by hemochromatosis. Forward and reverse sequencing of HFE exons 2, 3, 4, and 5, and of portions of HFE introns 2, 4, and 5 was carried out on biological samples taken from twenty hemochromatosis probands who lacked C282Y homozygosity, C282Y/H63D compound heterozygosity, or H63D homozygosity. Four probands had

DECODED  
DNA

novel HFE coding region mutations. Probands 1 and 2 were heterozygous for previously undescribed mutations: exon 2, nt 314T→C (314C; I105T), and exon 2, nt 277G→C (277C; G93R), respectively; these probands were also heterozygous for H63D and C282Y, respectively. Probands 3 and 4 were heterozygous for an HFE mutation in exon 2, nt 193A→T (193T; S65C).  
5 Twelve other probands did not have an exon 2 HFE exon mutation; four were heterozygous for H63D. In probands 1,  
10 2, 3, and 4, the amino acid substitutions I105T, G93R, and S65C (respectively) occurred on separate chromosomes from those with the C282Y or H63D mutations. In 176 normal control subjects, two were heterozygous for S65C; I105T and G93R were not detected in controls. Nine probands were  
15 heterozygous and two probands were homozygous for a base-pair change at intron 2, nt 4919T/C (SEQ ID NO:27). Heterozygosity for a base-pair change in intron 4 (nt 6884T→C) was detected only in probands 3 and 4, both of whom also had S65C and HLA-A32. The intron 2 mutation is not diagnostic of an iron disorder and appears randomly in  
20 the population. One proband was heterozygous for a base-pair change at intron 5 (nt 7055A→G).

The data described herein indicate that, in addition to the C282Y and H63D HFE mutations, the HFE exon and intron 5 mutations described herein are diagnostic (and  
25 prognostic) of iron disorders.

#### Pathology of iron overload

Iron plays an essential role in normal growth and development, but in elevated concentrations, iron is a toxic inorganic molecule and is the leading cause of death in  
30 children by poisoning. It has been implicated in the pathophysiology of a number of common diseases, e.g., hepatitis, cancer, heart disease, reperfusion injury,

rheumatoid arthritis, diabetes, AIDS, and psychological abnormalities (e.g. depression).

The incidence of cancer (especially liver cancer) rises dramatically in the course of hemochromatosis. Iron, acting alone or in synergy with other environmental agents, catalyzes free radical formation. These free radicals which mediate tissue damage also cause DNA double strand breaks and oncogene activation. Iron may also play a role in the pathogenesis of rheumatic diseases and in predisposition to heart disease. High levels of iron can also cause diabetes with 2% of diabetics being hemochromatosis patients. High levels of iron may also affect the disease progression of many viral diseases. Individuals infected with such viruses as hepatitis (e.g., hepatitis B or C) or HIV should be tested for HFE mutations because of the impact increased iron stores have on the treatment and prognosis of such diseases.

Excessive iron stores and iron deposition is also a major contributing factor in the pathology and treatment of non-valvular heart disease. These conditions include dilated cardiomyopathy cased by deposition of iron in myocardial fibers; myocardial injury the product of anthracycline cardiomyopathy and re-perfusion injury. Increased iron stores may also be a contributing factor in myocardial infarction due to atherosclerosis. Some evidence suggests a significant increase in the incidence of reported heart disease in probands (cardiac symptoms-32%, insulin-dependent diabetes-18%, cardiac arrhythmia-17%, clinically significant coronary artery atherosclerosis-9%, and congestive heart failure-7%. Cardiac complications have been detected in 30% of patients. These include EKG abnormalities, congestive heart failure and cardiac arrhythmias. An increased frequency of HFE mutations in

DRAFT  
SUGGESTED  
EDITS

individuals with porphyria cutanea tarda indicates that HFE mutations may predispose an individual to developing this syndrome.

The effect of iron overload is irreparable damage to vital organs and a multiplicity of associated pathologies described above. The multiplicity of clinical symptoms (and associated pathologies) often causes misdiagnosis of hemochromatosis or failure to diagnose hemochromatosis.

Untreated hemochromatosis is characterized by iron overload of parenchymal cells, which is toxic and the probable cause of various complications including cirrhosis, and liver cancer, arthropathy, hypogonadotropic hypogonadism, marrow aplasia, skin disorders, diabetes mellitus, and cardiomyopathy. There are 1.5 to 2 million active cases in the U.S. of which 40% have progressive liver disease because they have not been properly diagnosed or treated.

In untreated hemochromatosis, iron is universally deposited in the hepatocytes of the liver. The iron is found primarily in the cytoplasm of hepatocytes, and by electron microscopy in lysosomal vacuoles, and in more severe cases iron has also been reported deposited in mitochondria. Other liver toxins such as alcohol, and hepatitis exacerbate the damage caused by the iron deposition. Patients with hemochromatosis are advised not to drink, because of increased liver damage, or to smoke, as iron deposition can also occur in the lungs.

Individuals which are homozygous (and to a lesser extent heterozygous) for an HFE mutation are at risk for developing increased levels of blood lead. Thus, it is important to identify heterozygous as well as homozygous patients.

Identification and detection of mutations in the HFE gene are critical to understanding the general mechanisms of iron disorders and diagnosing iron-related pathologies.

Nucleic acid-based assays for HFE mutations

A biological sample containing RNA or DNA is obtained from an individual and the nucleic acid extracted. Optionally, the nucleic acid is amplified according to standard procedures such as PCR. A nucleic acid polymorphism, e.g., a single base pair polymorphism, is detected using methods well known in the art of molecular biology. For example, a mutation is detected using a standard sequencing assay, nucleic acid hybridization, e.g., using standard Southern, Northern, or dot blot hybridization assay systems and an HFE-specific oligonucleotide probe, restriction enzyme fragment polymorphism analysis, oligonucleotide ligation assay (OLA; Nikerson et al., 1990, Nucl. Acids Res. 87:8923-8927), primer extension analysis (Nikiforov et al., 1994, Nucl. Acids Res. 22:4167-4175), single strand conformation polymorphism (SSCP) analysis, allele-specific PCR (Rust et al., 1993, Nucl. Acids Res. 6:3623-3629), denaturing gradient gel electrophoresis (DGGE), fluorescent probe melting curve analysis (Bernard et al., 1998, Am. J. Pathol. 153:1055-61), RNA mismatch cleavage assay, capillary hybridization, or TaqMan™ assay (PE Applied Biosystems, Foster City, CA). Nucleic acid hybridization assays are also carried out using a bioelectronic microchip technology known in the art, e.g., that described in Sosnowski et al., 1997, Proc. Natl. Acad. Sci. U.S.A. 94:1119-1123; Cheng et al. 1998, Nature Biotechnology 16:541-546; or Edman et al., 1997, Nucl. Acids Res. 25:4907-4914.

Detection of mutations using antibodies and other HFE ligands

Anti-HFE antibodies are known in the art, e.g., those described by Feder et al., 1997, J. Biol. Chem. 272:14025-14028, or are obtained using standard techniques. Such antibodies can be polyclonal or monoclonal. Polyclonal antibodies can be obtained, for example, by the methods described in Ghose et al., Methods in Enzymology, Vol. 93, 326-327, 1983. An HFE polypeptide, or an antigenic fragment thereof, is used as an immunogen to stimulate the production of HFE-reactive polyclonal antibodies in the antisera of animals such as rabbits, goats, sheep, rodents and the like. HFE antibodies specific for mutated HFE gene products are raised by immunizing animals with a polypeptide spanning the mutation, e.g., a polypeptide which contains the mutations described herein. For example, the entire  $\alpha 1$  domain of a mutant HFE gene product is used as an immunogen. Monoclonal antibodies are obtained by the process described by Milstein and Kohler in Nature, 256:495-97, 1975, or as modified by Gerhard, Monoclonal Antibodies, Plenum Press, 1980, pages 370-371. Hybridomas are screened to identify those producing antibodies that are highly specific for an HFE polypeptide containing a mutation characteristic of an iron metabolism abnormality or clinical hemochromatosis.

Preferably, the antibody has an affinity of at least about  $10^5$  liters/mole, preferably at least  $10^6$  liters/mole, more preferably at least  $10^8$  liters/mole, and most preferably, an affinity of at least about  $10^9$  liters/mole.

Antibodies specific for the wild type HFE can also be used to diagnose hemochromatosis or iron metabolism abnormalities. Such antibodies are also useful research tools to identify novel mutations indicative of iron disorders or hemochromatosis. A reduction in binding to a

wild type HFE-specific antibody indicates the presence of a mutation. Antibody binding is detected using known methods. For example, an ELISA assay involves coating a substrate, e.g., a plastic dish, with an antigen, e.g., a patient-derived biological sample containing an HFE gene product. An antibody preparation is then added to the well. Antibodies specific for a mutant HFE gene product bind or fail to bind to a patient-derived sample in the well. Non-binding material is washed away and a marker enzyme e.g., horse radish peroxidase or alkaline phosphatase, coupled to a second antibody directed against the antigen-specific primary antibody is added in excess and the nonadherent material is washed away. An enzyme substrate is added to the well and the enzyme catalyzed conversion is monitored as indicative of presence of the mutation. Antibodies are also labelled with various sizes of colloidal gold particles or latex particles for detection of binding.

The invention employs not only intact monoclonal or polyclonal antibodies, but also an immunologically-active antibody fragment, for example, a Fab or (Fab)<sub>2</sub> fragment; an antibody heavy chain, an antibody light chain; a genetically engineered single-chain Fv molecule (Ladner et al., U.S. Patent No. 4,946,778).

Example 1: Selection and Characterization of Subjects

All individuals studied were Caucasians, 18 years of age or older, and from central Alabama. Twenty probands were identified that were either heterozygous for C282Y or H63D, or lacked these mutations. Hemochromatosis is typically diagnosed by detecting elevated saturation of transferrin, with elevated serum ferritin levels, combined with liver biopsy. Each proband patient described below was previously diagnosed to have hemochromatosis by the working diagnostic criterion for hemochromatosis of the American

College of Pathologists (elevated fasting transferrin saturation of greater than 60% saturation for males and greater than 50% saturation for females) on at least two occasions in the absence of other known causes. Probands were interviewed regarding their general medical history, diet (including estimated iron content and ethanol consumption), medicinal iron use, receipt of blood transfusion, prior significant hemorrhage, blood donation for transfusion and/or therapeutic phlebotomy, and pregnancy and lactation. Each proband was also evaluated for viral hepatitis B and C and other hepatic disorders, excess ethanol intake, and hereditary, and acquired anemia. Iron overload was defined as evidence of systemic iron overload demonstrated by otherwise unexplained elevated serum ferritin concentration ( $\geq 300$  ng/mL in men,  $\geq 200$  ng/mL in women), increased hepatic iron content determined using hepatic biopsy specimens, or iron  $>4$  g mobilized by phlebotomy. Complications of iron overload were evaluated and treated, and therapeutic phlebotomy was performed using standard methods. HFE mutation analysis for C282Y and H63D and human leukocyte antigen (HLA) immunophenotyping or molecular typing were performed using known methods. In some family members, HLA haplotyping had been performed previously for other disease associations, or their HLA type could be deduced from analysis of their kinship and HFE genotyping results. Measurement of serum iron and other clinical laboratory parameters and analysis of hepatic biopsy specimens were performed using routine methods. Control subjects (n=176) who were in apparently good health and were unrelated to the hemochromatosis probands were recruited from the general population. Iron parameters were measured and HLA typing was performed in two control

subjects after HFE genotyping revealed that they had the S65C mutation.

Example 2: HFE Gene Analysis

PCR amplification was used to detect mutations.

5 Genomic DNA was prepared from peripheral blood buffy coat or saliva using the QIAampBlood Kit (QIAGEN, Valencia, CA) or FTA Paper and FTA purification reagent (Fitzco Inc., Maple Plain, MN), respectively. Fragments were amplified from genomic DNA using eLONGase (Life Technologies, Gaithersburg, MD) or HotStarTaq DNA polymerase (QIAGEN, Valencia, CA).  
10 Primers used to amplify each exon are shown in Table 3.

Table 4: Human HFE genomic DNA

	1 ggatccttta accgaggaga ttattatgc cggagctctg aagcagcaat ctcagttttt
15	61 gtgatagtga gcaaagaact acaaactaac accaaaatgc aagcttaaag caaagtttat
20	121 tgaagcacaa taatacactc tgagggacag cgggcttatt tctgcgaagt gaactcagca
25	181 ctctttaca gagctcaagg tgctttatg gggtttgtgg ggaggagttg agttttgggc
30	241 tgtatctgag tgacaggatg atgttattt attgaagttt atagctatac aatctaaaat
35	301 taaactgtgc atggctttac ctataatttg ttaagaaaag cctcccaggg atgggggggc
40	361 aaaactgtat gtaaattcta ttataatgtat ggcatgtga acttgggtg aacttgaaga
45	421 caggcttttgc tgggttttttgc catgtgccac cttaggaaat ttccacctgt acccttcctt
	481 ctctttctcc aggatatttt ggcacagac ttatcataa actccatccc ttagggtggc
	541 attagggttag tcttggcct gaatttaggt gggccagtgg ctgtcttagt gacagccttt
	601 ccgcctcttttctcc ctgtcatccc ctcccaactg ctaatgtcta actacctaacc aattaccat
	661 taaatcagtg tggctgggtt taggagcagg cctcaatatg tttaatcatt ctccagataaa
	721 tcccaataact gtaaagtttgc taaaacactt gtcagataat tcaattatga aggctgtggc
	781 acgtgttca gtaggatcta attggtaat gttatgactt aattaatttgc aatcaaaaaaa
	841 caaaatgaaa aagctttata tttctaagtc aaataagaca taagttggc taaggttgag
	901 ataaaatttt taaatgtatg attgaatttt gaaaatcata aatatttaaa tatctaaagt
	961 tcagatcaga acattgcgaa gctactttcc ccaatcaaca acaccccttc agatttaaa
	1021 aaccaagggg gacactggat cacctgttgc ttcacaagca ggtaccccttc

DRAFT

gctgttaggag  
1081 agagagaact aaagttctga aagacctgtt gctttcacc aggaagttt  
actgggcattc  
1141 tcctgagcct aggcaatagc tgttagggta cttctggagc catccccgtt  
5 tccccgcccc  
1201 cccaaaagaag cgaggatcta acggggacgt gcggccagag ctggggaaat  
gggcccgcga  
1261 gccaggccgg cgcttcctt cctgatgctt ttgcagaccg cggtcctgca  
ggggcgcttg  
10 1321 ctgcgtgagt ccgagggtcg cgggcgaact aggggcgcgg cgggggtgga  
aaaatcgaaa  
1381 ctagctttt ctttgcgtt gggagttgc taactttgga ggacctgctc  
aaccataatc  
1441 gcaagccctt ctccctactt tctgcgtcca gacccctgta gggagtgct  
15 accactgaac  
1501 tgcagatagg ggtccctcgc cccaggacct gccccctccc ccggctgtcc  
cggtctgcg  
1561 gagtgacttt tggaaccgcc cactcccttc ccccaactag aatgctttt  
aataaatctc  
20 1621 gtatgttcc acttgagctg agctaagcct ggggctcctt gaacctggaa  
ctcggggtta  
1681 ttccaaatgt cagctgtgca gtttttccc cagtcatctc caaacaggaa  
gttcttccct  
1741 gagtgcttgc cgagaaggct gagcaaacc acagcaggat ccgcacgggg  
tttccacctc  
25 1801 agaacgaatg cggtggcggt tgggggcgcg aaagagtggc gttggggatc  
tgaattcttc  
1861 accattccac ccactttgg tgagacctgg ggtggaggtc tctagggtgg  
gaggctcctg  
30 1921 agagaggcct acctcgggcc tttccccact cttggcaatt gttctttgc  
ctggaaaatt  
1981 aagtatatgt tagtttgaa cgtttgaact gaacaattct ctttcggct  
aggctttatt  
2041 gatttgcattt gtgcgtgtt attaagaggc ctctctacaa agtactgata  
atgaacatgt  
35 2101 aagcaatgca ctcacttcta agttacattc atatctgatc ttatgttatt  
ttcaactaggc  
2161 ataggggaggt aggagctaatt aatacgtttta tttactaga agttaactgg  
aattcagatt  
40 2221 atataactct ttcaaggta caaagaacat aaataatctg gttttctgtat  
gttatttcaa  
2281 gtactacagc tgcttctaattt cttagttgac agtgcatttg ccctgttagt  
tagcacatgt  
2341 ttctgtgggt cacacgcccgg cctcagcaca gcactttgag ttttggtaact  
acgtgtatcc  
45 2401 acattttaca catgacaaga atgaggcatg gcacggcctg cttcctggca  
aatttattca  
2461 atggtacacg gggctttgggt ggcagagctc atgtctccac ttcatagcta  
tgattcttaa  
50 2521 acatcacact gcatttagagg ttgaataata aaatttcatg ttgagcagaa  
atattcattt  
2581 ttacaatgt taaatgagtc ccagccatgt gttgcactgt tcaagcccc  
agggagagag  
55 2641 cagggaaaca agtcttacc ctttgcattt ttgcattcta gtggggagaga  
tgacaataag  
2701 caaatgagca gaaagatata caacatcagg aaatcatggg ttttgtgaga  
agcagagaaag  
2761 tcagggcaag tcactctggg gctgacactt gagcagagac atgaaggaaa  
taagaatgt  
60 2821 attgactggg agcagtattt cccaggaaaa ctgagtgggc ctggcaagt  
ggattaaaaaa

D  
E  
B  
E  
R  
E  
K  
H  
O  
N  
G  
S  
O  
T

2881 gcgggttttc tcagcaactac tcatgtgtgt gtgtgtgggg ggggggggcgg  
cgtgggggtg  
2941 ggaagggggg ctaccatctg cattaggat gtcttagcagt atcctgtcct  
ccctactcac  
5 3001 taggtgctag gagcaactccc ccagtcttga caacaaaaaa tgtctctaaa  
cttgccaca  
3061 tgtcacctag tagacaaact cctggtaag aagctcggt tgaaaaaaaaat  
aaacaagttag  
3121 tgctggggag tagaggccaa gaagtaggta atgggctcag aagaggagcc  
acaaaacaagg  
10 3181 ttgtgcaggc gcctgttaggc tgtggtgtga attctagcca aggagtaaca  
gtgatctgtc  
3241 acaggctttt aaaagattgc tctggctgct atgtggaaag cagaatgaag  
ggagcaacag  
15 3301 taaaaggcagg gagccagcc aggaagctgt tacacagtcc aggcaagagg  
tagtggagtg  
3361 ggctgggtgg gaacagaaaaa gggagtgaca aaccattgtc tcctgaatat  
attctgaagg  
20 3421 aagttgctga aggattctat gttgtgtgag agaaagagaa gaattggctg  
ggtgttagtag  
3481 ctcatgccaa ggaggaggcc aaggagagca gattcctgag ctcaggagtt  
caagaccacg  
3541 ctggcaaca cagcaaaacc cttctctac aaaaaataca aaaatttagct  
gggtgtggtg  
25 3601 gcatgcacccat gtgatcctag ctactcgaaa ggctgaggtg gagggtatttg  
cttgagccca  
3661 ggaagtttag gctgcagtga gccatgactg tgccactgta cttcagcccta  
ggtgacagag  
3721 caagaccctg tctccctga cccccctgaaa aagagaagag ttaaagttga  
cttggatctt  
3781 tatttttaattt ttattggctt gagcagtggg gtaattggca atgccatttc  
tgagatggtg  
3841 aaggcagagg aaagagcagt ttggggtaaa tcaaggatct gcatttggac  
atgttaagtt  
35 3901 tgagattcca gtcaggcttc caagtggtgaa ggccacatag gcagttcagt  
gtaagaattc  
3961 aggaccaagg cagggcacgg tggctcaattt ctgtaatccc agcactttgg  
tggtgaggc  
40 4021 aggttagatca tttgaggtca ggagtttgag acaagttgg ccaacatgg  
gaaaccccat  
4081 gtctactaaa aataaaaaaa ttagcctggt gtggggcgac acgcctata  
tcccaaggttt  
4141 tcaggaggtt tagttaggag aatcccttga acccaggagg tgcagggttgc  
atgttagtga  
45 4201 gatttgccca ctgcactcca gcctgggtga tagagtgaga ctctgtctca  
aaaaaaaaaa  
4261 aaaaaaaaaa aactgaagga attattcctc aggattttgg  
tctaattttgc  
4321 cctgagcaccc aactcctgag ttcaactacc atggcttagac acaccta  
attttctaga  
50 4381 atccaccagc ttttagtggag tctgtctaat catgagtattt ggaataggat  
ctggggggcag  
4441 tgagggggtg gcagccacgt gtggcagaga aaagcacaca aggaaagagc  
acccaggact  
55 4501 gtcataatgca agaaagacag gactgcaact cacccttcac aaaatgagga  
ccagacacag  
4561 ctgatggat gagttgatgc aggtgtgtgg agcctcaaca tcctgctccc  
ctcctactac  
4621 acatggttaa ggcctgttgc tctgtctcca gttcacact ctctgcacta  
cctcttcatg  
60 4681 ggtgccttag agcaggaccc tggtctttcc ttgtttgaag ctttggctca

cgtggatgac  
4741 cagctgttcg tttcttatga tcatacgatc cgccgtgtgg agccccgaac  
tccatgggtt  
4801 tccagtagaa tttcaagcca gatgtggctg cagctgagtc agagtctgaa  
agggtggat  
4861 cacatgttca ctgttgactt ctggactatt atggaaaatc acaaccacag  
caagggtatg  
4921 tggagagggg gcctcacctt cctgagggttgcagagcttt tcatctttc  
atgcacatctt  
4981 aaggaaacag ctgaaagtct gaggtcttgtt gggagcaggg aagagggaaag  
gaatttgctt  
5041 cctgagatca tttggtcctt gggatggtg gaaataggga cctattcctt  
tggttgcagt  
5101 taacaaggct ggggattttt ccagagtccc acaccctgca ggtcatcctg  
ggctgtgaaa  
5161 tgcaagaaga caacagtacc gagggctact ggaagtacgg gtatgatggg  
caggaccacc  
5221 ttgatttctg ccctgacaca ctggatttggagcagcaga acccaggggcc  
tggcccacca  
5281 agctggagtg ggaaaggcac aagattcggg ccaggcagaa cagggcctac  
ctggagaggg  
5341 actgcccctgc acagctgcag cagttgctgg agctggggag aggtgtttt  
gaccaacaag  
5401 gtatggtgaa aacacacttc tgcccctata ctctagtgcc agagtggagg  
aggttgcagg  
5461 gcacgaaatc cctgggttggagttcagagg tggctgaggc tgtgtgcctc  
tccaaattct  
5521 gggaaaggac tttctcaatc cttagtctc taccttataa ttgagatgt  
tgagacagcc  
5581 acaagtcatg gtttaatattt ctttctcca tgcataatggc tcaaaggaa  
gtgtctatgg  
5641 cccttgcattt ttatthaacc aataatcttt tttatattt tacctgttaa  
aaattcagaa  
5701 atgtcaaggc cgggcacggg ggctcacccc tttatccca gcactttggg  
aggccgaggc  
5761 ggggtgttac aaggtcagga gttttagacc agcctgacca acatggtgaa  
accgtctct  
5821 aaaaaataac aaaaattagc tggcacatgt catgcgcacc tttatccca  
gctaatttgg  
5881 aggctgaggc aggagcatcg cttaaacctg ggaagcgaa gttgcactga  
gccaagatcg  
5941 cgccactgca ctccagccta ggcagcagag tgagactcca ttttttttt  
aaaaaaaaaaa  
6001 aaaaagagaa ttcaagatc tcaatcatca tatgaataacc aggacaaaat  
atcaatgt  
6061 gccacttac agatgttt  
aacatagca  
6121 taatctactga agtacccat cttacaagtc cgcttcttataaataatgcct  
ccttaggttga  
6181 cccaggtgaa actgaccatc tgtattcaat cttttcaat gcacataaaag  
ggcaattttt  
6241 tctatcgaa caaagaacat gggtaacaga tatgtatatt tacatgtgag  
gagaacaagc  
6301 tgatctgact gctctccaaag tgacactgtg ttagagtcacatggac  
acaaaatggt  
6361 gtcctcctg tagcttgaaa tttctgaaa aggttatttc cttccctccaa  
cctatagaag  
6421 gaatgttggaa ttccagtcctt cctggcaagg gtaaacagat cccctcttc  
catcttcct  
6481 ctttcctgtc aagtgcctcc tttgggtgaag gtgacacatc atgtgacatc  
ttcagtgacc

6541 actctacggt gtcgggcctt gaactactac ccccagaaca tcaccatgaa  
     gtggctgaag  
 6601 gataaggcagc caatggatgc caaggagttc gaacctaaag acgtattgcc  
     caatggggat  
 5     6661 gggacctacc agggctggat aaccttggct gtacccctg ggaaagagca  
     gagatatacg  
 6721 tgccaggtgg agcacccagg cctggatcag cccctcattg ttagtctgggg  
     tatgtgactg  
 6781 atgagagcca ggagctgaga aaatctattt ggggttgaga ggagtgcctg  
 10     aggaggtaat  
 6841 tatggcagtg agatgaggat ctgctttt ttagggatg ggctgagggt  
     ggcaatcaaa  
 6901 ggcttaact tgcttttct gtttttagac cctcaccgtc tggcacccta  
     gtcattggag  
 15     6961 tcatacgtgg aattgtgtt tttgtcgta tcttggcat tgaaatttt  
     ttcataatat  
 7021 taaggaagag gcagggttca agttagttagg aacaaggggg aagtctctt  
     gtacctctgc  
 20     7081 cccagggcac agtgggaaga gggcagagg ggatctggca tccatggaa  
     gcattttct  
 7141 catttatatt ctttggggac accagcagct ccctggaga cagaaaataa  
     tggttctccc  
 7201 cagaatgaaa gtctctaatt caacaaacat cttcagagca cctactattt  
     tgcaagagct  
 25     7261 gtttaaggtt gtacaggggc tttgaggttg agaagtcact gtggctattc  
     tcagaaccca  
 7321 aatctggtag ggaatgaaat tgatagcaag taaatgttgt taaagaagac  
     cccatgagg  
 30     7381 cctaaagcag gcaggaagca aatgtttagg gtgtcaaagg aaagaatgat  
     cacattcagc  
 7441 tggggatcaa gatagccttc tggatcttga aggagaagct ggattccatt  
     aggtgagg  
 7501 gaagatgtat ggaggcttac acagacggag caaccatgcc aagttaggaga  
     gtataaggca  
 35     7561 tactgggaga ttagaaataa ttactgtacc ttaaccctga gtttgcttag  
     ctatcactca  
 7621 ccaattatgc atttctaccc cctgaacatc tgtggtgttag ggaaaagaga  
     atcagaaaga  
 40     7681 agccagctca tacagagtcc aagggtctt tggatattt ggatgtatgc  
     actgggtgt  
 7741 cattgaagaaa tcctaagaaaa ggaggaccac gatctccctt atatggtaa  
     tggttgtta  
 7801 agaagttaga tgagaggtga ggagaccagt tagaaagcca ataagcattt  
     ccagatgaga  
 45     7861 gataatggtt ctgaaatcc aatagtcccc aggtctaaat tgagatgggt  
     gaatgaggaa  
 7921 aataaggaag agagaagagg caagatggtg cctaggttt tgatgcctct  
     ttcctgggtc  
 50     7981 tcttgcctcc acaggaggag ccatggggca ctacgtctt gctgaacgtg  
     agtgacacgc  
 8041 agcctgcaga ctcactgtgg gaaggagaca aaactagaga ctc当地agagg  
     gagtgcatt  
 8101 atgagcttt catgtttcag gagaggttg aacctaaaca tagaaattgc  
     ctgacgaact  
 55     8161 cttgtatcc agcctctct gttcatttcc tcaaaaagat ttccccattt  
     aggtttctga  
 8221 gttcctgcat gccgggtgatc cctagctgtg acctctcccc tggactgtc  
     tctcatgaac  
 60     8281 ctcaagctgc atctagaggc ttccttcatt tcctccgtca cctcagagac  
     atacacctat  
 8341 gtcatttcat ttcctat tggaaagagga ctccttaat ttggggact

tacatgattc  
 8401 attttaacat ctgagaaaag ctttgaaccc tgggacgtgg ctagtcataa  
     ccttaccaga  
 8461 ttttacaca tgtatctatg cattttctgg acccgttcaa cttttcttt  
     5      gaatcctctc  
 8521 tctgtgttac ccagtaactc atctgtcacc aagccttggg gattcttcca  
     tctgattgtg  
 8581 atgtgagtgt cacagctatg aaggctgtac actgcacgaa tggaaagaggc  
     actgtcccc  
 10     8641 gaaaaagcat catggctatc tgtggtagt atgatgggtg ttttagcag  
     gtaggaggca  
 8701 aatatcttga aagggttgtt gaagaggtgt ttttctaatt tggcatgaag  
     gtgtcataca  
 15     8761 gatttgcaaa gttaatggc gccttcattt gggatgtac tctagtattc  
     cagacctgaa  
 8821 gaatcacaat aattttctac ctggtctctc cttgttctga taatgaaaat  
     tatgataagg  
 8881 atgataaaaag cacttacttc gtgtccgact cttctgagca cctacttaca  
     tgcattactg  
 20     8941 catgcacttc ttacaataat tctatgagat aggtactatt atccccattt  
     ctttttaaa  
 9001 tgaagaaaagt gaagtaggcc gggcacgggt gctcacgcct gtaatcccag  
     cactttggga  
 9061 ggccaaagcg ggtggatcac gaggtcagga gatcgagacc atcctggcta  
     25     acatgggtgaa  
 9121 accccatctc taataaaaat aaaaaaaaaatt agctgggcgt ggtggcagac  
     gcctgtactc  
 9181 ccagctactc ggaaggctga ggcaggagaa tggcatgaac ccaggaggca  
     gagcttgcag  
 30     9241 tgagccgagt ttgcgccact gcactccagc ctaggtgaca gagtgagact  
     ccatctcaaa  
 9301 aaaataaaaaa taaaaataaa aaaatgaaaa aaaaaagaaaa gtgaagtata  
     gagtatctca  
 9361 tagttgtca gtgatagaaa caggttcaa actcagtcaa tctgaccgtt  
     tgatacatct  
 9421 cagacaccac tacattcagt agtttagatg cctagaataa atagagaagg  
     aaggagatgg  
 9481 ctcttctctt gtctcattgt gtttcttctg aatgagctt aatcacatga  
     agggaaacag  
 40     9541 cagaaaacaa ccaactgatc cttagctgtc atgtttcctt taaaagtccc  
     tgaaggaagg  
 9601 tccttggaaatg tgactccctt gtcctctgt tgctctctt ggcattcatt  
     tctttggacc  
 9661 ctacgcaagg actgtattt gtggggacag cttagtggccc tgctggcctt  
     45     cacacacgg  
 9721 gtcctcccta ggccagtgcc tctggagtca gaactctggt ggtatccccc  
     tcaatgaagt  
 9781 ggagtaagat ctctcatttt gagatggat aatgaaagcc accaagtggc  
     tttagaggatg  
 50     9841 cccaggctt tccatggagc cactgggtt ccgggtgcaca taaaaaaaaa  
     aatctaacca  
 9901 ggacatttag gaattgcttag attctggaa atcagttcac catgttcaaa  
     agagtctttt  
 9961 tttttttttt gagactctat tgcccaggct ggagtgcataat ggcattgatct  
     55     cgctcaactg  
 10021 taacctctgc ctcccagggtt caagcgatcc tcctgtctca gcctcccaag  
     tagctggat  
 10081 tacaggcgtg caccaccatg cccggctaat ttttgtattt ttagtagaga  
     cagggttca  
 60     10141 ccatgttggc caggctggc tcgaactctc ctgaccctgt gatccgcctg  
     cctcggcctc

10201 ccaaagtgt gagattacag gtgtgagcca ccctgcccag ccgtcaaaag  
     agtcttaata  
 10261 tatatatcca gatggcatgt gtttacttta tgttactaca tgcacttggc  
     tgcatataatg  
 5   10321 tggtaacaagg attctgtctt gaagggcagg tgcttcagga taccatatac  
     agctcagaag  
 10381 tttcttctt aggcataaa ttttagcaaa gatatctcat ctcttcttt  
     aaaccatttt  
 10441 cttttttgt ggtagaaaa gttatgtaga aaaaagtaaa tgtgatttac  
 10   gctcattgt  
 10501 gaaaagctat aaaatgaata caattaaagc tgttatttaa ttagccagtg  
     aaaaactatt  
 10561 aacaacttgt ctattacctg ttagtattat tgttgcatta aaaatgcata  
     tactttaata  
 15   10621 aatgtacatt gtattgtata ctgcattgatt ttattgaagt tcttgttcat  
     cttgcattt  
 10681 tacttaatcg ctttgcatt ttggagacat ttattttgtct tctaatttct  
     ttacattttg  
 10741 tcttacggaa tatttcatt caactgtggt agccgaatta atcgtgttcc  
 20   ttcactctag  
 10801 ggacattgtc gtctaaatgg taagacattt gttattttac cagcaaacc  
     ttctgaaagc  
 10861 atatgacaaa ttatttctct cttaatatct tactatactg aaagcagact  
     gctataaggc  
 25   10921 ttcacttact cttcaccc tcataaggaaata tgttacaatt aatttattag  
     gtaaggcattt  
 10981 gttttatatt ggttttattt cacctgggtc gagattcaaa gaaacacccc  
     agtcttcaca  
 30   11041 gtaacacatt tcactaacac atttactaaa catcagcaac tggccctgt  
     taatttttt  
 11101 atagaaaattt ttaagtcctc attttcttc ggtgttttt aagcttaatt  
     tttctggctt  
 11161 tattcataaa ttcttaaggt caactacatt tgaaaaatca aagacctgca  
     ttttaattt  
 35   11221 ttattcacct ctggcaaaac cattcacaaa ccatggtagt aaagagaagg  
     gtgacaccc  
 11281 gtggccatag gtaaatgtac cacgggtggc cggtgaccag agatgcagcg  
     ctgagggtt  
 11341 tcctgaaggt aaaggaataa agaatgggtg gaggggcgtg cactggaaat  
     cacttggtag  
 40   11401 gaaaagcccc tgaaaattt gaaaaacaaa caagaaacta cttaccagct  
     atttgaattt  
 11461 ctggaaatcac aggcattgc tgagctgcct gaactggaa cacaacagaa  
     ggaaaacaaa  
 45   11521 ccactctgat aatcattgag tcaagtacag caggtgattt aggactgct  
     agaggtacag  
 11581 gccaaaattt ttatgttta ttataataat gtcatttat aatactgtca  
     gtattttata  
 50   11641 aaacatttt cacaactca cacacattt aaaaacaaaac actgtctcta  
     aaatccccaa  
 11701 atttttctata aactcagttt taaaactaact tttttcaaa ccacaatctg  
     attnaacaat  
 11761 gactatcatt taaatatttc tgactttcaa attaaagatt ttcacatgca  
     ggctgatatt  
 55   11821 tgtaattgtg attctctctg taggctttgg gtataatgtg ttctttct  
     ttttgcattc  
 11881 agcgattAAC ttctacactc taacatgttag aatgttacta caatattaaa  
     gtattttgt  
 60   11941 tgacaatttt atttggaaagc ctaggatgcg ttgacatcct gcatgcatt  
     attacttgat  
 12001 atgcattcat tctggtatct caaggattct atttctgagt aattgtttaa

ggtgtagaag  
12061 agatagat ggtggattt gagttgatac ttatataattt tctatttctt  
ggatggatga  
12121 atttgtacat taaaagtttt ccatgg

5 (SEQ ID NO:27; GENBANK® Accession No. Z92910)

Exon 1 spans nt 1028-1324, inclusive; exon 2 spans nt 4652-4915, inclusive; exon 3 spans nt 5125-5400, inclusive; exon 4 spans nt 6494-6769, inclusive; exon 5 spans nt 6928-7041, inclusive; exon 6 spans nt 7995-9050, 10 inclusive, and exon 7 spans nt 10206-10637, inclusive. Intron 4 spans nt 6770-6927, inclusive, and intron 5 spans nt 7042-7994, inclusive.

Total RNA for the RT-PCR was prepared from 1.5 mL of whole blood using the RNeasy Blood Kit (QIAGEN, Valencia, CA). Total messenger RNA encoding the HFE gene was transcribed and amplified with the primers shown above using standard methods, e.g., the Superscript ONE-STEP RT- PCR System (Life Technologies, Gaithersburg, MD). The amplified product was directly subcloned into the pCR2.1-TOPO vector and transfected into TOP 10 bacteria (Invitrogen, Carlsbad, CA). Plasmid DNAs isolated from the subcloning were prepared with the UltraClean Mini Prep Kit (Mo Bio, Solana Beach, CA) and sequenced.

DNA sequencing was performed using the ABI Prism 25 BigDye Terminator Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems, Foster City, CA) and analyzed on an ABI Prism 377.

To detect mutations in exon 2 of the HFE gene, the genomic DNA of probands and normal control subjects were 30 amplified and subjected to a dot blot hybridization assay. 1.0  $\mu$ l of each resulting PCR product was then applied to a Magna Graph nylon membrane (MSI, Westboro, MA). The membranes were treated with 0.5 N NaOH/1.5 M NaCl to denature the DNA, neutralized with 0.5 M Tris-HCl

(pH 8.0)/1.5 M NaCl, and rinsed with 2 × SSC (1 × SSC = 0.15 M NaCl/0.015 M sodium citrate, pH 7.0). The DNAs were fixed on the membrane by UV irradiation using a Stratalinker 1800 (Stratagene, Inc., La Jolla, CA). The ECL 5 3'-oligolabelling and detection system (Amersham, Arlington Heights, IL) was used for synthesis of labeled oligonucleotide probes, hybridization, and signal detection. The oligonucleotide sequences used to detect each point mutation were (substituted bases are shown as upper case 10 letters):

Table 5: Oligonucleotide Probes

Point Mutation	Oligonucleotide
G93R mutation	gtctgaaaCggtggtt (SEQ ID NO:28)
I105T mutation	actttctggactaCtatgg (SEQ ID NO:29)
S65C mutation	atcatgagTgtcgccgt (SEQ ID NO:30)

For signal detection, each oligonucleotide was labeled with fluorescein-11-dUTP using terminal deoxynucleotidyl transferase according to the manufacturer's instructions (Amersham Ltd., Arlington Heights, IL). The membranes were prehybridized in 5 × SSC, 0.1% Hybridization buffer component, 0.02% SDS, 5% LiquidBlock at 42°C for approximately 2 hours. Labelled oligonucleotide probes were added to individual bags containing the membranes and prehybridization buffer and incubated at 42°C overnight. 15 20 The blots were washed twice with 5 × SSC, 0.1% SDS for 5 minutes at room temperature. Stringency washes for hybridization with oligonucleotides having the sequence of SEQ ID NO: 30 or 28 were performed twice in 0.2 × SSC/0.1% 25

SDS for 15 minutes at 42°C. Membranes probed with an oligonucleotide having the sequence of SEQ ID NO:29 was washed twice under less stringent conditions (0.5 × SSC/0.1% SDS, 15 minutes at 42°C). Detection of a fluorescent signal was performed according to standard methods.

Example 3: Characterization of Probands

The mean age of the twenty probands was 44 ± 11 years (range 27-62 years); thirteen (65.0%) were men and seven (35.0%) were women. Eleven had iron overload. One had hepatic cirrhosis, two had diabetes mellitus, four had arthropathy, and two had hypogonadotrophic hypogonadism. One proband also had hereditary stomatocytosis, another had beta-thalassemia trait, a third had ethanol intake >60 g daily, and a fourth had porphyria cutanea tarda. No proband had evidence of excess oral or parenteral iron intake, or of viral hepatitis B or C. At diagnosis of hemochromatosis, evaluation for common HFE mutations revealed that eleven probands were C282Y heterozygotes, five were H63D heterozygotes, and four did not inherit C282Y or H63D.

The mean age of the initial 176 control subjects was 52 ± 15 years (range 18-86 years); 79 (44.9%) were men and 97 (55.1%) were women. There was no significant difference in the mean ages of men and women. Frequencies of HFE genotypes among the control subjects are shown in Table 6. These values are similar to those previously reported from normal persons from the same geographic area.

Table 6. Frequencies of *HFE* Genotypes in Alabama Subjects.

<i>HFE</i> Genotype	Hemochromatosis Probands with "Atypical" <i>HFE</i> Genotypes, % (n)	Normal Control Subjects, % (n)
wt/wt	15.00 (3)	60.23 (106)
C282Y/wt	45.00 (9)	13.06 (23)
H63D/wt	20.00 (4)	15.34 (27)
S65C/wt	5.00 (1)	1.14 (2)
C282Y/S65C	5.00 (1)	0
C282Y/G93R	5.00 (1)	0
H63D/I105T	5.00 (1)	0
H63D/C282Y	0	6.82 (12)
H63D/H63D	0	3.41 (6)

Results are expressed as percentage (n). The wild-type (wt) allele was defined as the *HFE* configuration in which the mutations C282Y, H63D, S65C, I105T, or G93R were not detected.

Example 4: Identification of novel HFE Mutations in  
Hemochromatosis Probands

The following novel mutations (missense mutations) were identified in probands 1 and 2: exon 2, nt 314T→C (I105T), and exon 2, nt 277G→C (G93R), respectively (Table 7; Figs. 1 and 2). Probands 3 and 4 had a S65C mutation. The S65C mutation has been observed in hemochromatosis patients but has not been deemed to be indicative of a disease state. In contrast, the data presented herein indicate that the S65C mutation is diagnostic of a disease state. This result is surprising in view of earlier observations. Other than C282Y or H63D, no HFE exon mutations were detected in the remaining sixteen of the twenty probands (Table 6). Nine probands were heterozygous for a base-pair change at intron 2, nt 4919T/C (SEQ ID NO:27); two probands were homozygous for this base-pair change. Heterozygosity for a base-pair change in intron 4 (nt 6884T→C) was detected only in probands 3 and 4, both of whom also inherited S65C. One proband was heterozygous for a base-pair change at intron 5, nt 7055A→G.

Using dot blot methodology, heterozygosity for the S65C mutation was detected in two of 176 normal control subjects (Table 6). The G93R or I105T mutations were not detected in normal control subjects (Tables 6 and 8).

Example 5: Association of Novel HFE Coding Region Mutations to C282Y and H63D and HFE Intron Alleles

In proband 1, two mutations of exon 2 (H63D and I105T) were detected. After subcloning the genomic fragment, the subclones revealed that these mutations occurred on separate chromosomes; this observation was confirmed by family studies indicating segregation of I105T

Table 7. Phenotypes and Uncommon *HFE* Genotypes in Alabama Subjects\*

Subject†	Age (years), Sex	<i>HFE</i> Genotype	HLA Type	Transferrin Saturation, ‡	Serum Ferritin, ng/mL	Hepatocyte Iron Grade	Phlebotomy Y, Units
Proband 1	52 M	H63D/I105T	A2, 3; B7, 7	62	868	2+	20
Proband 2‡	40 M	C282Y/G93R	A2, 3; B7, 62	78	861	4+	34
Proband 3§	47 F	C282Y/S65C	A2, 32; B8, 44; Bw4, 6; Cw5, 7	90	281	3+	37
Proband 4**	81 F	S65C/wt	A2, 32; B14, 62	100	5,135	N.D.	37
Normal Control 1	28 M	S65C/wt	A2, 31; B35, 60	28	141	N.D.	N.D.
Normal Control 2	69 M	S65C/wt	A24, 26; B8, B37; Bw4, 6; Cw6, 5 (or 7)	42	747	2+	N.D.

\*Serum transferrin saturation, serum ferritin concentration, and percutaneous hepatic biopsy were performed before therapeutic phlebotomy was initiated. Reference ranges for these parameters are 15 - 45%; 20 - 300 ng/mL (men) and 20 - 200 ng/mL (women); and 0 -1+, respectively. Iron depletion (serum ferritin < 20 ng/mL) was induced by removing the indicated numbers of units of blood. None of these persons had evidence of hepatic cirrhosis, diabetes mellitus, hemochromatosis-associated arthropathy, hypogonadotrophic hypogonadism, other endocrinopathy, or cardiomyopathy. N.D. = not done. The mutations indicated are exon 4, nt 84G>A (C282Y); exon 2, nt 187C>G (H63D); exon 2, nt 314T>C (I105T); exon 2, nt 277G>C (G93R); and exon 2, nt 193A>T (S65C). The wild-type (wt) allele was defined as an *HFE* allele in which the mutations C282Y, H63D, S65C, I105T, or G93R were not detected.

†Countries of origin: Probands 1 and 2, England; Proband 3, Wales, England, and Americas (Cherokee); Proband 4, England and Ireland; Normal Control 1, England; Normal Control 2, The Netherlands.

‡The father and sister of Proband 2 are presently undergoing therapy for hemochromatosis and iron overload, but their clinical and genetic data were unavailable.

§Proband 3 had porphyria cutanea tarda alleviated with therapeutic phlebotomy.

\*\*Proband 4 had hereditary stomatocytosis unaffected by phlebotomy treatments. 37 units of blood were removed by phlebotomy before treatment was discontinued due to stroke apparently unrelated to anemia or iron overload (post-treatment serum ferritin 1,561 ng/mL). Her 59 year-old daughter (who does not have hereditary stomatocytosis) had transferrin saturation 42%, serum ferritin 62 ng/mL, HLA type A1, 32; B14, 15; Bw4, 6; Cw3, 8, and *HFE* genotype S65C/H63D. These data permitted assignment of the S65C mutation in this family to a haplotype carrying HLA-A32; linkage of S65C and HLA-A32 was also observed in the family of Proband 3.

Table 8. Frequencies of HFE Alleles in Alabama Subjects.

	wt*	C282Y	H63D	S65C†	I105T	G93R
Hemochromatosis Probands with "Atypical" HFE Genotypes (n = 20)	0.500	0.275	0.125	0.050	0.025	0.025
Normal Control Subjects (n = 176)	0.750	0.099	0.145	0.006	‡	‡

The wild-type (wt) allele was defined as an *HFE* allele in which the mutations C282Y, H63D, S65C, I105T, or G93R were not detected.

†S65C was detected in 2 of 22 (0.091) proband chromosomes and in 2 of 266 (0.0075) control chromosomes that did not bear the C282Y, H63D, S65C, I105T, or G93R mutation.

‡Based on this data set, the frequency of the I105T and G93R *HFE* alleles is estimated to be < 0.0028, respectively.

and H63D (Fig. 1). In proband 2 (HFE genotype C282Y/G93R), RT-PCR analysis (with subsequent subcloning and sequencing) revealed that these HFE mutations occurred on separate chromosomes. Family studies of proband 3 (HFE genotype C282Y/S65C) indicated that the C282Y and S65C HFE alleles segregated independently, establishing their occurrence on separate chromosomes (Table 7, Fig. 3).

In proband 1 (HFE genotype H63D/I105T), the I105T mutation was co-inherited with HLA-A3, B7. In probands 3 and 4 and their respective families, S65C was inherited on the same chromosome as HLA-A32, indicating that HLA-A32 is a marker for chromosomes bearing the S65C mutation, and individuals with HLA-A32 have an increased risk for developing hemochromatosis. The G93R mutation is associated with HLA-A2, and individuals with that haplotype have an increased risk for developing hemochromatosis. The I105T mutation is associated with HLA-A3, e.g., HLA-A3, B7, and individuals with that haplotype have an increased risk for developing hemochromatosis. Among twenty probands tested, the nucleotide polymorphism in intron 4 (nt 6884T→C) was detected in probands 3 and 4, both of whom also had S65C. Subjects that tested positive for the S65C mutation all were found to have the intron 4 (6884T→C) mutation, including two probands (3 and 4), their families, and two normal controls.

Example 6: HFE Coding Region Mutations and Clinical Phenotype

The I105T and G93R mutations were associated with a hemochromatosis clinical phenotype in probands 1 and 2 who also inherited H63D and C282Y, respectively. Proband 3 had clinical evidence of hemochromatosis, iron overload, and porphyria cutanea tarda associated with compound heterozygosity for C282Y and S65C. Proband 4 had severe iron overload associated with heterozygosity for S65C and

co-inheritance of hereditary stomatocytosis (Table 7). The sister of proband 1 (HFE genotype I105T/wt) was not completely evaluated for hyperferritinemia (Fig. 1). Otherwise, family members of probands who were heterozygous 5 for novel HFE mutations described herein had little or no evidence of abnormal iron parameters, a hemochromatosis phenotype, or of iron overload (Table 7 and 9; Figs. 1 and 3). Normal Control 1 who had HFE genotype S65C/wt had a

Table 9. Hemochromatosis (HC) Family study/patient

Subject/Age/Sex	HLA Type	exon 2	exon 4	intron 4	Tf sat**	Ftn* ng/ml	Diagnosis/Hepatocyte Iron grade
Proband 1/57M (201)	A2,3;B7,7	H63D/H,1105T/1	WT	T	62	868	HC/2+
brother/45M (204)		H63D/H	WT	T*	31	186	
sister/50F (203)	A3,3;B7,7	1105T	WT*	T*	37	576	
daughter/31F (301)	A32,68;B7,44	1105T/1	WT*	T*	31	56	
son/27M (302)	A2,68;B7,44	H63D/H	WT*	T*	33	44	
Proband 2/40M	A2,3;B7,62	G93R/G	C282Y/C	T	78	861	HC/4+
Father		WT	C282Y/Y*	T*			HC
Sister		G93R/G	C282Y/C*	T*			HC
Proband 3/47(201)	A2,32;B8,44	S65C/S	C282Y/C	T/C	90	281	HC/3+
brother/45M(202)	A2,32;B44,51	S65C/S	WT	T/C	33	42	
mother/81F(102)	A2,2;B8,51	WT	C282Y/C	T*	NT	NT	
sister/33F(204)	A2,7;B27,51	WT	WT	T*	NT	NT	
brother/35M(203)	A2,7;B27,51	WT	WT*	T*	NT	NT	
sister		WT	C282Y/C*	T*			
sister		S65C/S	WT*	T/C*			
Proband 4/81F	A2,32;B14,62	S65C/S	WT	T/C	1.00	S135	HC+stomatocytosis
daughter/59*	A1,32;B14,15	H63D/H,S65C/S	WT*	T/C	42	62	
Control 1/28M	A2,31;B35,60	S65C/S	WT	T/C	28	141	
Control 2/69M	A24,26;B8,37	S65C/S	WT	T/C	42	747	2+

\*RE cut

\*\*normal (15-45%)

\*\*\*20-300ng/ml (men)  
2C-200ng/ml (women)

normal iron phenotype (Table 7). Normal Control 2, who also had the HFE genotype S65C/wt, had hyperferritinemia and mildly increased stainable hepatocellular iron deposition, but had no symptoms or other objective findings attributable to iron overload (Table 7). These data indicate that S65C heterozygosity is associated with abnormal iron parameters.

Example 7: HLA gene linkage

In the family of proband 1, the I105T mutation was linked to HLA-A3, B7, markers which are often linked to the C282Y mutation and its ancestral haplotype. HLA-A3, B7 is also significantly more common among C282Y-negative hemochromatosis probands than in normal control subjects tested. S65C was linked to HLA-A32 in probands 3 and 4 (and their respective families). The base-pair change in intron 4 (nt 6884T→C) was detected only in probands who inherited the S65C mutation. These data indicate that an intron 4 mutation (nt 6884→C) is a marker for chromosomes bearing the S65C HFE allele. Three of four probands who inherited mutated HFE exon 2 mutations described herein also inherited the C282Y or H63D mutations on separate chromosomes. In a fourth proband, the co-inheritance of S65C heterozygosity and hereditary stomatocytosis was associated with severe iron overload.

Altered interactions of transferrin receptor, transferrin, and C282Y and H63D mutant HFE protein contribute to the pathology of hemochromatosis. The S65C, G93R, and I105T mutations are located within the  $\alpha 1$  domain: in the  $\alpha 1$  helix of the HFE class I-like heavy chain (I105T and G93R), and at the tip of the A chain loop of the  $\beta$ -pleated sheet (S65C). These mutations affect the overall structure of the HFE gene product, and specifically affect the salt bridge between residues H63 and D95. The I105T substitution also inhibits proper folding of the  $\alpha 1$  domain

of the HFE gene product, and specifically affects the hydrophobicity of the hydrophobic F pocket.

Other embodiments are within the following claims.

0982100-1011604